Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1824333 | 0.75 | TSHR (0.39) | ADRB2ADRB1ADRB3 | |
| SCHEMBL5680337 | 0.74 | — | — | |
| SCHEMBL5680332 | 0.72 | TSHR (0.38) | ADRB2ADRB1ADRB3 | |
| SCHEMBL1740885 | 0.70 | LMNA (0.30) | — | |
| SCHEMBL14643301 | 0.66 | ABCB1 (0.38) | — | |
| SCHEMBL13134669 | 0.66 | ABCB1 (0.38) | — | |
| SCHEMBL1738678 | 0.63 | MEN1 (0.32) | ADRB2ADRB1ADRB3 | |
| SCHEMBL1685076 | 0.62 | HPGD (0.46) | ADRB2ADRB1ADRB3 | |
| SCHEMBL5707623 | 0.62 | NPC1 (0.31) | ADRB2ADRB1ADRB3 | |
| SCHEMBL5707590 | 0.62 | NPC1 (0.33) | ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2319853-B1 | Process for the production of 2'-branched nucleosides | IDENIX PHARMACEUTICALS INC (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-2319853-A1 | Process for the production of 2'-branched nucleosides | Idenix (Cayman) Limited (KY) | 2011-05-11 | — | — | EP | disclosed |
| US-7598373-B2 | Process for the production of 2-C-methyl-D-ribonolactone | IDENIX PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-1585529-A4 | PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES | IDENIX CAYMAN LTD (KY) | 2008-05-28 | — | — | EP | disclosed |
| EP-1585529-A2 | PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES | Idenix (Cayman) Limited (KY) | 2005-10-19 | — | — | EP | disclosed |
| US-20050020825-A1 | Process for the production of 2'-branched nucleosides | IDENIX PHARMACEUTICALS LLC | 2005-01-27 | — | — | US | disclosed |
| WO-2004052899-A2 | PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES | IDENIX (CAYMAN) LIMITED (KY) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020825-A1 | Process for the production of 2'-branched nucleosides | RNGTT, MTAP, NSUN2 | ADRB2 1570/4885ADRB1 1819/4885ADRB3 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.